Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

Marit Jalink*, Sigbjørn Berentsen, Jorge J. Castillo, Steven P. Treon, Marjan Cruijsen, Bruno Fattizzo, Ramona Cassin, Despina Fotiou, Efstathios Kastritis, Masja De Haas, Liesbeth E.M. Oosten, Henrik Frederiksen, Andrea Patriarca, Shirley D'Sa, Josephine M.I. Vos


Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Udgave nummer20
Sider (fra-til)2002-2005
StatusUdgivet - 18. nov. 2021

Bibliografisk note

Funding Information:
Conflict-of-interest disclosure: S.B. received lecture honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Janssen-Cilag, and True North Therapeutics and consultancy and advisory board honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Momenta Pharmaceuticals, and SOBI. J.J.C. received research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, and TG Therapeutics. S.P.T. received research support and consulting fees from Janssen and Abbvie/Pharmacyclics and Beigene and research support from BMS, Eli Lilly, and X4. B.F. received consultancy honoraria from Momenta, Alexion, Amgen, and Novartis. E.K. received research support from Amgen and Janssen and honoraria from Amgen, Janssen, Genesis Pharma, Takeda, and Pfizer. H.F. received funding outside this work from Alexion, Gilead, Abbvie, Janssen Pharmaceuticals, and Novartis. A.P. received honoraria from Icyte and Novartis and was on the advisory board for Amgen and Novartis. S.D. received honoraria from Janssen, BeiGene, and Sanofi; research funding from BeiGene and Janssen; was on advisory boards for BeiGene and Sanofi; and was on the speakers bureau for Janssen and BeiGene. J.M.I.V. received travel reimbursement from Celgene and was on the advisory board for Sanofi. All remaining authors declare no competing financial interests.